Comments
Marksans Pharma’s arm, Time-Cap Laboratories Inc, is withdrawing an unspecified number of Ibuprofen tablets, manufactured in Goa, in multiple strengths from the American market on account of a deviation from good manufacturing norms, according to the latest USFDA report.
The reason for recall is “CGMP Deviations: various strengths of Ibuprofen tablets/caplets are being recalled due to complaints of odour related to CGMP deficiencies,” the latest enforcement report of the US health regulator said.
The tablets in the strengths of 200mg, 400 mg, 600 mg and 800 mg and caplets in the strength 200 mg were manufactured for Time Cap Labs Inc by Marksans Pharma at its Goa facility, it added.
The nationwide, voluntary and ongoing recall by Time-Cap Laboratories, Inc is a Class II recall, the United States Food and Drug Administration (USFDA) said. According to the USFDA, a class II recall is initiated in a situation “in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”
Ibuprofen is a non-steroidal anti-inflammatory drug used for treating pain. Headquartered at Mumbai, Marksans Pharma is a global pharma major that offers contract research and manufacturing services (CRAMS) to pharmaceutical companies.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.